May 03, 2021
2 min watch
Save
VIDEO: Researchers investigate biomarkers to predict ranibizumab treatment intervals
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective from the virtual ARVO meeting, Zdenka Haskova, MD, PhD, explains potential predictive biomarkers for ranibizumab treatment intervals in patients with macular edema associated with retinal vein occlusion.
Published by:
Sources/Disclosures
Collapse
Source:
Li YY, et al. Prediction of ranibizumab injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE phase 3 trials. Presented at: Association for Research in Vision and Ophthalmology annual meeting; May 1-7, 2021 (virtual meeting).
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.